308 related articles for article (PubMed ID: 10898541)
1. Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
Gornet JM; Azoulay D; Lévi F; Yovine A; Misset JL; Goldwasser F
Anticancer Drugs; 2000 Apr; 11(4):263-8. PubMed ID: 10898541
[TBL] [Abstract][Full Text] [Related]
2. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Stickel F; Jüngert B; Brueckl V; Schirner I; Brueckl WM; Männlein G; Hegewald J; Mühldorfer S; Bittorf B; Hohenberger W; Hahn EG; Wein A
Anticancer Drugs; 2003 Oct; 14(9):745-9. PubMed ID: 14551509
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
[TBL] [Abstract][Full Text] [Related]
4. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
Garufi C; Bria E; Vanni B; Zappalà AM; Sperduti I; Terzoli E
Br J Cancer; 2003 Nov; 89(10):1870-5. PubMed ID: 14612895
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
Garufi C; Dogliotti L; D'Attino RM; Tampellini M; Aschelter AM; Pugliese P; Perrone M; Nisticó C; Comis S; Terzoli E
Cancer; 2001 Feb; 91(4):712-20. PubMed ID: 11241238
[TBL] [Abstract][Full Text] [Related]
7. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
Bécouarn Y; Gamelin E; Coudert B; Négrier S; Pierga JY; Raoul JL; Provençal J; Rixe O; Krisch C; Germa C; Bekradda M; Mignard D; Mousseau M
J Clin Oncol; 2001 Nov; 19(22):4195-201. PubMed ID: 11709562
[TBL] [Abstract][Full Text] [Related]
8. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G
Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152
[TBL] [Abstract][Full Text] [Related]
9. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Ychou M; Conroy T; Seitz JF; Gourgou S; Hua A; Mery-Mignard D; Kramar A
Ann Oncol; 2003 Mar; 14(3):481-9. PubMed ID: 12598357
[TBL] [Abstract][Full Text] [Related]
10. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M
Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419
[TBL] [Abstract][Full Text] [Related]
11. Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
Shimonov M; Hayat H; Chaitchik S; Brener J; Schachter P; Czerniak A
Chemotherapy; 2005 May; 51(2-3):111-5. PubMed ID: 15886466
[TBL] [Abstract][Full Text] [Related]
12. [A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Sagawa T; Tsuji Y; Takayanagi N; Hirayama Y; Sakamaki S; Chiba H; Iyama S; Oku T; Sato Y; Takahashi M; Takayama T; Niitsu Y
Gan To Kagaku Ryoho; 2003 Apr; 30(4):537-43. PubMed ID: 12722689
[TBL] [Abstract][Full Text] [Related]
13. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
[TBL] [Abstract][Full Text] [Related]
14. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
Janinis J; Papakostas P; Samelis G; Skarlos D; Papagianopoulos P; Fountzilas G
Ann Oncol; 2000 Feb; 11(2):163-7. PubMed ID: 10761750
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
[TBL] [Abstract][Full Text] [Related]
16. An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Pasinetti N; Marini G
Oncology; 2005; 69(4):283-9. PubMed ID: 16282707
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Bathe OF; Dowden S; Sutherland F; Dixon E; Butts C; Bigam D; Walley B; Ruether D; Ernst S
BMC Cancer; 2004 Jul; 4():32. PubMed ID: 15245580
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Goldwasser F; Gross-Goupil M; Tigaud JM; Di Palma M; Marceau-Suissa J; Wasserman E; Yovine A; Misset JL; Cvitkovic E
Ann Oncol; 2000 Nov; 11(11):1463-70. PubMed ID: 11142487
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
